Published in BMC Cancer on December 21, 2006
BIBW2992, an irreversible EGFR/HER2 inhibitor highly effective in preclinical lung cancer models. Oncogene (2008) 6.82
Detection of knockdown resistance (kdr) mutations in Anopheles gambiae: a comparison of two new high-throughput assays with existing methods. Malar J (2007) 3.20
Molecular testing guideline for selection of lung cancer patients for EGFR and ALK tyrosine kinase inhibitors: guideline from the College of American Pathologists, International Association for the Study of Lung Cancer, and Association for Molecular Pathology. Arch Pathol Lab Med (2013) 2.66
Hypoxic and Ras-transformed cells support growth by scavenging unsaturated fatty acids from lysophospholipids. Proc Natl Acad Sci U S A (2013) 2.57
Detection of macrolide resistance in Mycoplasma pneumoniae by real-time PCR and high-resolution melt analysis. Antimicrob Agents Chemother (2008) 2.56
COLD-PCR-enhanced high-resolution melting enables rapid and selective identification of low-level unknown mutations. Clin Chem (2009) 2.17
High resolution melting analysis for rapid and sensitive EGFR and KRAS mutation detection in formalin fixed paraffin embedded biopsies. BMC Cancer (2008) 2.16
High resolution melting applications for clinical laboratory medicine. Exp Mol Pathol (2008) 1.92
KRAS mutation: comparison of testing methods and tissue sampling techniques in colon cancer. J Mol Diagn (2009) 1.78
A multicenter blinded study to evaluate KRAS mutation testing methodologies in the clinical setting. J Mol Diagn (2009) 1.76
Evaluation of high-resolution melting analysis as a diagnostic tool to detect the BRAF V600E mutation in colorectal tumors. J Mol Diagn (2009) 1.72
Dramatic reduction of sequence artefacts from DNA isolated from formalin-fixed cancer biopsies by treatment with uracil- DNA glycosylase. Oncotarget (2012) 1.69
High resolution melting for mutation scanning of TP53 exons 5-8. BMC Cancer (2007) 1.65
A rapid high-throughput method for the detection and quantification of RNA editing based on high-resolution melting of amplicons. Nucleic Acids Res (2007) 1.62
EGFR mutation heterogeneity and the mixed response to EGFR tyrosine kinase inhibitors of lung adenocarcinomas. Oncologist (2012) 1.53
HER3 and downstream pathways are involved in colonization of brain metastases from breast cancer. Breast Cancer Res (2010) 1.48
Rapid detection of carriers with BRCA1 and BRCA2 mutations using high resolution melting analysis. BMC Cancer (2008) 1.37
Clinical pharmacogenomic testing of KRAS, BRAF and EGFR mutations by high resolution melting analysis and ultra-deep pyrosequencing. BMC Cancer (2011) 1.27
High-resolution DNA melt curve analysis of the clustered, regularly interspaced short-palindromic-repeat locus of Campylobacter jejuni. Appl Environ Microbiol (2007) 1.22
Limited copy number-high resolution melting (LCN-HRM) enables the detection and identification by sequencing of low level mutations in cancer biopsies. Mol Cancer (2009) 1.17
Lack of EGFR-activating mutations in European patients with triple-negative breast cancer could emphasise geographic and ethnic variations in breast cancer mutation profiles. Breast Cancer Res (2011) 1.14
A high-throughput protocol for mutation scanning of the BRCA1 and BRCA2 genes. BMC Cancer (2011) 1.12
KRAS mutation testing in metastatic colorectal cancer. World J Gastroenterol (2012) 1.11
Simultaneous mutation detection of three homoeologous genes in wheat by High Resolution Melting analysis and Mutation Surveyor. BMC Plant Biol (2009) 1.09
AXL is a key regulator of inherent and chemotherapy-induced invasion and predicts a poor clinical outcome in early-stage colon cancer. Clin Cancer Res (2013) 1.06
Mutation detection of epidermal growth factor receptor and KRAS genes using the smart amplification process version 2 from formalin-fixed, paraffin-embedded lung cancer tissue. J Mol Diagn (2010) 1.02
Epidermal growth factor receptor gene amplification and gefitinib sensitivity in patients with recurrent lung cancer. J Cancer Res Clin Oncol (2007) 0.96
Sensitive and specific KRAS somatic mutation analysis on whole-genome amplified DNA from archival tissues. J Mol Diagn (2009) 0.96
Classification of fowl adenovirus serotypes by use of high-resolution melting-curve analysis of the hexon gene region. J Clin Microbiol (2008) 0.95
Computer-aided identification of polymorphism sets diagnostic for groups of bacterial and viral genetic variants. BMC Bioinformatics (2007) 0.95
Comparison of COBAS 4800 KRAS, TaqMan PCR and high resolution melting PCR assays for the detection of KRAS somatic mutations in formalin-fixed paraffin embedded colorectal carcinomas. Virchows Arch (2013) 0.95
Sensitive detection of KRAS mutations in archived formalin-fixed paraffin-embedded tissue using mutant-enriched PCR and reverse-hybridization. J Mol Diagn (2009) 0.95
KRAS mutation detection and prognostic potential in sporadic colorectal cancer using high-resolution melting analysis. Br J Cancer (2010) 0.94
PIK3CA hotspot mutation scanning by a novel and highly sensitive high-resolution small amplicon melting analysis method. J Mol Diagn (2010) 0.93
Campylobacter jejuni and Campylobacter coli genotyping by high-resolution melting analysis of a flaA fragment. Appl Environ Microbiol (2009) 0.93
Rapid and reliable detection of glucose-6-phosphate dehydrogenase (G6PD) gene mutations in Han Chinese using high-resolution melting analysis. J Mol Diagn (2010) 0.92
High-resolution melting analysis as a powerful tool to discriminate and genotype Pseudomonas savastanoi pathovars and strains. PLoS One (2012) 0.91
Multiplex amplification coupled with COLD-PCR and high resolution melting enables identification of low-abundance mutations in cancer samples with low DNA content. J Mol Diagn (2011) 0.90
Is high resolution melting analysis (HRMA) accurate for detection of human disease-associated mutations? A meta analysis. PLoS One (2011) 0.90
Determination of EGFR and KRAS mutational status in Greek non-small-cell lung cancer patients. Oncol Lett (2015) 0.89
Detection of monoclonal immunoglobulin heavy chain gene rearrangement (FR3) in Thai malignant lymphoma by High Resolution Melting curve analysis. Diagn Pathol (2010) 0.87
Eprobe mediated real-time PCR monitoring and melting curve analysis. PLoS One (2013) 0.87
Detection of α-thalassemia-1 Southeast Asian and Thai type deletions and β-thalassemia 3.5-kb deletion by single-tube multiplex real-time PCR with SYBR Green1 and high-resolution melting analysis. Korean J Lab Med (2011) 0.87
Genetic screening of Fabry patients with EcoTILLING and HRM technology. BMC Res Notes (2011) 0.86
Investigating the potential role of genetic and epigenetic variation of DNA methyltransferase genes in hyperplastic polyposis syndrome. PLoS One (2011) 0.85
Integrated mutation, copy number and expression profiling in resectable non-small cell lung cancer. BMC Cancer (2011) 0.85
Comparative examination of various PCR-based methods for DNMT3A and IDH1/2 mutations identification in acute myeloid leukemia. J Exp Clin Cancer Res (2014) 0.85
KRAS, NRAS and BRAF mutations in Greek and Romanian patients with colorectal cancer: a cohort study. BMJ Open (2014) 0.85
High-resolution melting analysis for accurate detection of BRAF mutations: a systematic review and meta-analysis. Sci Rep (2014) 0.85
Eprobe-mediated screening system for somatic mutations in the KRAS locus. Oncol Rep (2015) 0.84
A closed-tube methylation-sensitive high resolution melting assay (MS-HRMA) for the semi-quantitative determination of CST6 promoter methylation in clinical samples. BMC Cancer (2012) 0.84
Genetic diversity of Dientamoeba fragilis isolates of irritable bowel syndrome patients by high-resolution melting-curve (HRM) analysis. Parasitol Res (2009) 0.83
Docetaxel plus cetuximab as second-line treatment for docetaxel-refractory oesophagogastric cancer: the AGITG ATTAX2 trial. Br J Cancer (2013) 0.83
DNA methylation subgroups and the CpG island methylator phenotype in gastric cancer: a comprehensive profiling approach. BMC Gastroenterol (2014) 0.82
The Potential Power of Bar-HRM Technology in Herbal Medicine Identification. Front Plant Sci (2016) 0.82
PIK3CA mutations are frequently observed in BRCAX but not BRCA2-associated male breast cancer. Breast Cancer Res (2013) 0.82
The oncogenic properties of EWS/WT1 of desmoplastic small round cell tumors are unmasked by loss of p53 in murine embryonic fibroblasts. BMC Cancer (2013) 0.81
KRAS mutation detection by high-resolution melting analysis significantly predicts clinical benefit of cetuximab in metastatic colorectal cancer. Br J Cancer (2012) 0.81
Diagnostic accuracy of high resolution melting analysis for detection of KRAS mutations: a systematic review and meta-analysis. Sci Rep (2014) 0.81
The use of EGFR exon 19 and 21 unlabeled DNA probes to screen for activating mutations in non-small cell lung cancer. J Biomol Tech (2008) 0.81
Arl4c expression in colorectal and lung cancers promotes tumorigenesis and may represent a novel therapeutic target. Oncogene (2014) 0.81
High-resolution melting analysis (HRM) for differentiation of four major Taeniidae species in dogs Taenia hydatigena, Taenia multiceps, Taenia ovis, and Echinococcus granulosus sensu stricto. Parasitol Res (2016) 0.80
Assessment of high resolution melt analysis feasibility for evaluation of beta-globin gene mutations as a reproducible, cost-efficient and fast alternative to the present conventional method. Adv Biomed Res (2016) 0.79
Characterization of a novel tumorigenic esophageal adenocarcinoma cell line: OANC1. Dig Dis Sci (2014) 0.79
Detection of epidermal growth factor receptor mutations in formalin fixed paraffin embedded biopsies in Malaysian non-small cell lung cancer patients. J Biomed Sci (2013) 0.79
Rapid multiplex high resolution melting method to analyze inflammatory related SNPs in preterm birth. BMC Res Notes (2012) 0.79
Identification of six New World Leishmania species through the implementation of a High-Resolution Melting (HRM) genotyping assay. Parasit Vectors (2014) 0.79
Rapid detection and identification of Theileria equi and Babesia caballi by high-resolution melting (HRM) analysis. Parasitol Res (2013) 0.79
Optimization of routine KRAS mutation PCR-based testing procedure for rational individualized first-line-targeted therapy selection in metastatic colorectal cancer. Cancer Med (2013) 0.78
Detection of EGFR mutation in supernatant, cell pellets of pleural effusion and tumor tissues from non-small cell lung cancer patients by high resolution melting analysis and sequencing. Int J Clin Exp Pathol (2014) 0.78
Assessment for Melting Temperature Measurement of Nucleic Acid by HRM. J Anal Methods Chem (2016) 0.77
Discovery and Biological Evaluation of Novel Dual EGFR/c-Met Inhibitors. ACS Med Chem Lett (2014) 0.77
Differential Regulation of Gene Expression of Alveolar Epithelial Cell Markers in Human Lung Adenocarcinoma-Derived A549 Clones. Stem Cells Int (2015) 0.76
Development of a High-Resolution Melting Analysis Method for CYP2C19*17 Genotyping in Healthy Volunteers. Avicenna J Med Biotechnol (2016) 0.76
Biochip-based detection of KRAS mutation in non-small cell lung cancer. Int J Mol Sci (2011) 0.76
High-resolution melting (HRM) assay for the detection of recurrent BRCA1/BRCA2 germline mutations in Tunisian breast/ovarian cancer families. Fam Cancer (2014) 0.76
Current companion diagnostics in advanced colorectal cancer; getting a bigger and better piece of the pie. J Gastrointest Oncol (2017) 0.75
A rational two-step approach to KRAS mutation testing in colorectal cancer using high resolution melting analysis and pyrosequencing. BMC Cancer (2016) 0.75
Retracted Frequency of TP53 Mutations and its Impact on Drug Sensitivity in Acute Myeloid Leukemia? Indian J Clin Biochem (2012) 0.75
Oncogenic NRAS Primes Primary Acute Myeloid Leukemia Cells for Differentiation. PLoS One (2015) 0.75
Non-small cell lung cancer: the era of targeted therapy. Lung Cancer (Auckl) (2012) 0.75
High-resolution melting (HRM) re-analysis of a polyposis patients cohort reveals previously undetected heterozygous and mosaic APC gene mutations. Fam Cancer (2015) 0.75
Comparison of Direct Sequencing, Real-Time PCR-High Resolution Melt (PCR-HRM) and PCR-Restriction Fragment Length Polymorphism (PCR-RFLP) Analysis for Genotyping of Common Thiopurine Intolerant Variant Alleles NUDT15 c.415C>T and TPMT c.719A>G (TPMT*3C). Diagnostics (Basel) (2017) 0.75
A simple salting out procedure for extracting DNA from human nucleated cells. Nucleic Acids Res (1988) 77.80
Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med (2004) 71.08
EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science (2004) 61.56
EGF receptor gene mutations are common in lung cancers from "never smokers" and are associated with sensitivity of tumors to gefitinib and erlotinib. Proc Natl Acad Sci U S A (2004) 33.85
ras oncogenes in human cancer: a review. Cancer Res (1989) 22.03
The Catalogue of Somatic Mutations in Cancer (COSMIC). Curr Protoc Hum Genet (2008) 16.09
KRAS mutation status is predictive of response to cetuximab therapy in colorectal cancer. Cancer Res (2006) 13.98
KRAS mutations and primary resistance of lung adenocarcinomas to gefitinib or erlotinib. PLoS Med (2005) 13.40
Erlotinib in lung cancer - molecular and clinical predictors of outcome. N Engl J Med (2005) 13.01
High-resolution genotyping by amplicon melting analysis using LCGreen. Clin Chem (2003) 7.77
Sensitive sequencing method for KRAS mutation detection by Pyrosequencing. J Mol Diagn (2005) 6.00
Transforming genes of human bladder and lung carcinoma cell lines are homologous to the ras genes of Harvey and Kirsten sarcoma viruses. Proc Natl Acad Sci U S A (1982) 5.39
EGFR mutations in non-small-cell lung cancer: analysis of a large series of cases and development of a rapid and sensitive method for diagnostic screening with potential implications on pharmacologic treatment. J Clin Oncol (2005) 5.07
Blocking oncogenic Ras signaling for cancer therapy. J Natl Cancer Inst (2001) 4.25
Genotyping of single-nucleotide polymorphisms by high-resolution melting of small amplicons. Clin Chem (2004) 3.99
Detection of ras gene mutations in human lung cancers by single-strand conformation polymorphism analysis of polymerase chain reaction products. Oncogene (1990) 3.65
Mutations and addiction to EGFR: the Achilles 'heal' of lung cancers? Trends Mol Med (2004) 3.44
Amplicon DNA melting analysis for mutation scanning and genotyping: cross-platform comparison of instruments and dyes. Clin Chem (2006) 3.24
Sensitivity and specificity of single-nucleotide polymorphism scanning by high-resolution melting analysis. Clin Chem (2004) 2.91
Comparison of SYTO9 and SYBR Green I for real-time polymerase chain reaction and investigation of the effect of dye concentration on amplification and DNA melting curve analysis. Anal Biochem (2005) 2.18
Human malignant melanoma: detection of BRAF- and c-kit-activating mutations by high-resolution amplicon melting analysis. Hum Pathol (2005) 2.16
Demonstration of preferential binding of SYBR Green I to specific DNA fragments in real-time multiplex PCR. Nucleic Acids Res (2003) 2.01
Detection of K-ras mutations in lung carcinomas: relationship to prognosis. Clin Cancer Res (1996) 1.74
K-ras oncogene mutation as a prognostic marker in non-small cell lung cancer: a combined analysis of 881 cases. Carcinogenesis (1999) 1.67
Polymerase chain reaction-based K-ras mutation detection of pancreatic adenocarcinoma in routine cytology smears. Am J Clin Pathol (1996) 1.54
Implications and prognostic value of K-ras mutation for early-stage lung cancer in women. J Natl Cancer Inst (1999) 1.50
Prognostic significance of K-ras codon 12 mutations in patients with resected stage I and II non-small-cell lung cancer. J Clin Oncol (1999) 1.46
K-ras point mutation detection in lung cancer: comparison of two approaches to somatic mutation detection using ARMS allele-specific amplification. Clin Chem (2000) 1.40
Restriction endonuclease-mediated selective polymerase chain reaction: a novel assay for the detection of K-ras mutations in clinical samples. Am J Pathol (1998) 1.37
BRAF and c-kit gene copy number in mutation-positive malignant melanoma. Hum Pathol (2006) 1.35
Diagnostic biochip array for fast and sensitive detection of K-ras mutations in stool. Clin Chem (2002) 1.35
K-ras oncogene subtype mutations are associated with survival but not expression of p53, p16(INK4A), p21(WAF-1), cyclin D1, erbB-2 and erbB-3 in resected pancreatic ductal adenocarcinoma. Int J Cancer (2000) 1.27
Detection of EGFR- and HER2-activating mutations in squamous cell carcinoma involving the head and neck. Mod Pathol (2006) 1.23
Mutations of p53 and K-ras genes as prognostic factors for non-small cell lung cancer. Int J Oncol (1998) 1.19
High sensitivity scanning of colorectal tumors and matched plasma DNA for mutations in APC, TP53, K-RAS, and BRAF genes with a novel DHPLC fluorescence detection platform. Ann N Y Acad Sci (2004) 1.17
A sensitive fluorescence monitor for the detection of activated Ras: total chemical synthesis of site-specifically labeled Ras binding domain of c-Raf1 immobilized on a surface. Chem Biol (2001) 1.17
Detection of rare mutant K-ras DNA in a single-tube reaction using peptide nucleic acid as both PCR clamp and sensor probe. Nucleic Acids Res (2006) 1.16
Mutation scanning of the RET protooncogene using high-resolution melting analysis. Clin Chem (2006) 1.14
Unfavourable prognosis associated with K-ras gene mutation in pancreatic cancer surgical margins. Gut (2006) 1.11
Highly sensitive nonradioactive single-strand conformational polymorphism. Detection of Ki-ras mutations. Diagn Mol Pathol (1996) 1.07
Detection of infrequent and multiple K-ras mutations in human tumors and tumor-adjacent tissues. Anal Biochem (1997) 1.04
Sensitive and specific detection of K-ras mutations in colon tumors by short oligonucleotide mass analysis. Nucleic Acids Res (2004) 0.99
Predictive factors for pancreatic cancer in patients with chronic pancreatitis in association with K-ras gene mutation. Endoscopy (2004) 0.98
Detection of rare K-ras codon 12 mutations using allele-specific competitive blocker PCR. Mutat Res (2002) 0.98
Direct sequencing analysis of exon 1 of the c-K-ras gene shows a low frequency of mutations in human pancreatic adenocarcinomas. Oncogene (1989) 0.97
Sensitive detection of KIT D816V in patients with mastocytosis. Clin Chem (2006) 0.95
Simplified Reverse Dot Blot Analyses for Detecting of ras Oncogene Mutations. Mol Diagn (1997) 0.92
Automated constant denaturant capillary electrophoresis applied for detection of KRAS exon 1 mutations. Biotechniques (2001) 0.92
Rapid, comprehensive screening of the human medium chain acyl-CoA dehydrogenase gene. Mol Genet Metab (2004) 0.92
c-KIT mutation analysis for diagnosis of gastrointestinal stromal tumors in fine needle aspiration specimens. Cancer (2005) 0.89
Detection of c-kit exons 11- and 17-activating mutations in testicular seminomas by high-resolution melting amplicon analysis. Mod Pathol (2006) 0.89
Mutation detection in KRAS Exon 1 by constant denaturant capillary electrophoresis in 96 parallel capillaries. Anal Biochem (2002) 0.88
Molecular-clinical correlative studies in non-small cell lung cancer: application of a three-tiered approach. Lung Cancer (2001) 0.87
EGFR mutation status and prognosis for gefitinib treatment in Japanese lung cancer. Lung Cancer (2005) 0.86
The prognostic value of the presence of mutations at the codons 12, 13, 61 of K-ras oncogene in colorectal cancer. Anticancer Res (2000) 0.84
Clinicopathological significance of Ki-ras point mutation and p21 expression in benign and malignant exocrine tumors of the human pancreas. Int J Pancreatol (1996) 0.83
Evaluation of Her-2/neu gene status in osteosarcoma by fluorescence in situ hybridization and multiplex and monoplex polymerase chain reactions. Arch Pathol Lab Med (2006) 0.83
Colorectal cancer prognosis: is it all mutation, mutation, mutation? Gut (2005) 0.83
[Sensitive detection of K-ras oncogene codon 12 mutations by nested PCR using mismatched primers and selective digestion of non-mutated PCR fragments with restriction enzyme]. Rinsho Byori (1993) 0.80
Prognostic significance of epidermal growth factor receptor (EGFR) and c-erbB-2 protein overexpression in adenocarcinoma of the uterine cervix. Eur J Gynaecol Oncol (1996) 0.80
Frequent and focal FGFR1 amplification associates with therapeutically tractable FGFR1 dependency in squamous cell lung cancer. Sci Transl Med (2010) 6.39
The Hippo pathway and human cancer. Nat Rev Cancer (2013) 5.17
BRCA mutation frequency and patterns of treatment response in BRCA mutation-positive women with ovarian cancer: a report from the Australian Ovarian Cancer Study Group. J Clin Oncol (2012) 3.86
Empirical array quality weights in the analysis of microarray data. BMC Bioinformatics (2006) 3.54
Methylation-sensitive high resolution melting (MS-HRM): a new approach for sensitive and high-throughput assessment of methylation. Nucleic Acids Res (2007) 2.69
Denosumab induces tumor reduction and bone formation in patients with giant-cell tumor of bone. Clin Cancer Res (2012) 2.46
Molecular pathogenesis of osteosarcoma. DNA Cell Biol (2007) 2.31
Genome-wide association study identifies two susceptibility loci for osteosarcoma. Nat Genet (2013) 2.21
High resolution melting analysis for rapid and sensitive EGFR and KRAS mutation detection in formalin fixed paraffin embedded biopsies. BMC Cancer (2008) 2.16
Wnt inhibitory factor 1 is epigenetically silenced in human osteosarcoma, and targeted disruption accelerates osteosarcomagenesis in mice. J Clin Invest (2009) 2.09
Constitutional methylation of the BRCA1 promoter is specifically associated with BRCA1 mutation-associated pathology in early-onset breast cancer. Cancer Prev Res (Phila) (2010) 2.08
Dual targeting of the epidermal growth factor receptor using the combination of cetuximab and erlotinib: preclinical evaluation and results of the phase II DUX study in chemotherapy-refractory, advanced colorectal cancer. J Clin Oncol (2012) 1.95
A critical review of the role of Fc gamma receptor polymorphisms in the response to monoclonal antibodies in cancer. J Hematol Oncol (2013) 1.88
Clinical outcome and pathological features associated with NRAS mutation in cutaneous melanoma. Pigment Cell Melanoma Res (2011) 1.87
FGFR genetic alterations predict for sensitivity to NVP-BGJ398, a selective pan-FGFR inhibitor. Cancer Discov (2012) 1.83
Methylation-sensitive high-resolution melting. Nat Protoc (2008) 1.80
Detection of MGMT promoter methylation in normal individuals is strongly associated with the T allele of the rs16906252 MGMT promoter single nucleotide polymorphism. Cancer Prev Res (Phila) (2009) 1.78
A multicenter blinded study to evaluate KRAS mutation testing methodologies in the clinical setting. J Mol Diagn (2009) 1.76
Dramatic reduction of sequence artefacts from DNA isolated from formalin-fixed cancer biopsies by treatment with uracil- DNA glycosylase. Oncotarget (2012) 1.69
High resolution melting for mutation scanning of TP53 exons 5-8. BMC Cancer (2007) 1.65
Reducing sequence artifacts in amplicon-based massively parallel sequencing of formalin-fixed paraffin-embedded DNA by enzymatic depletion of uracil-containing templates. Clin Chem (2013) 1.62
RECK--a newly discovered inhibitor of metastasis with prognostic significance in multiple forms of cancer. Cancer Metastasis Rev (2007) 1.57
Sensitive Melting Analysis after Real Time- Methylation Specific PCR (SMART-MSP): high-throughput and probe-free quantitative DNA methylation detection. Nucleic Acids Res (2008) 1.57
Liposarcoma: molecular genetics and therapeutics. Sarcoma (2010) 1.55
Nonequivalent gene expression and copy number alterations in high-grade serous ovarian cancers with BRCA1 and BRCA2 mutations. Clin Cancer Res (2013) 1.54
Sequence artefacts in a prospective series of formalin-fixed tumours tested for mutations in hotspot regions by massively parallel sequencing. BMC Med Genomics (2014) 1.53
HER3 and downstream pathways are involved in colonization of brain metastases from breast cancer. Breast Cancer Res (2010) 1.48
Small changes in six-minute walk distance are important in diffuse parenchymal lung disease. Respir Med (2009) 1.47
The implications of heterogeneous DNA methylation for the accurate quantification of methylation. Epigenomics (2010) 1.45
Endobronchial ultrasound-guided transbronchial needle aspiration for the evaluation of suspected lymphoma. J Thorac Oncol (2010) 1.43
A new approach to primer design for the control of PCR bias in methylation studies. BMC Res Notes (2008) 1.42
Stress-induced cellular adaptive strategies: ancient evolutionarily conserved programs as new anticancer therapeutic targets. Bioessays (2014) 1.40
Rapid detection of carriers with BRCA1 and BRCA2 mutations using high resolution melting analysis. BMC Cancer (2008) 1.37
Correlation of mutation status and survival with predominant histologic subtype according to the new IASLC/ATS/ERS lung adenocarcinoma classification in stage III (N2) patients. J Thorac Oncol (2013) 1.32
BRCA1 promoter methylation in peripheral blood DNA of mutation negative familial breast cancer patients with a BRCA1 tumour phenotype. Breast Cancer Res (2008) 1.30
Differential tissue distribution of tryptophan hydroxylase isoforms 1 and 2 as revealed with monospecific antibodies. Brain Res (2006) 1.27
Comprehensive mapping of p53 pathway alterations reveals an apparent role for both SNP309 and MDM2 amplification in sarcomagenesis. Clin Cancer Res (2010) 1.26
Molecular profiling of giant cell tumor of bone and the osteoclastic localization of ligand for receptor activator of nuclear factor kappaB. Am J Pathol (2005) 1.26
Distinct clinical and pathological features are associated with the BRAF(T1799A(V600E)) mutation in primary melanoma. J Invest Dermatol (2006) 1.25
DNA methylation biomarkers in cancer: progress towards clinical implementation. Expert Rev Mol Diagn (2012) 1.24
Mutations in KIT occur at low frequency in melanomas arising from anatomical sites associated with chronic and intermittent sun exposure. Pigment Cell Melanoma Res (2010) 1.22
Impaired bone development and increased mesenchymal progenitor cells in calvaria of RB1-/- mice. Proc Natl Acad Sci U S A (2008) 1.22
Benefits and adverse events in younger versus older patients receiving neoadjuvant chemotherapy for osteosarcoma: findings from a meta-analysis. J Clin Oncol (2013) 1.21
BRAF/NRAS wild-type melanomas have a high mutation load correlating with histologic and molecular signatures of UV damage. Clin Cancer Res (2013) 1.18
Cost-benefit of minimally invasive staging of non-small cell lung cancer: a decision tree sensitivity analysis. J Thorac Oncol (2010) 1.18
Limited copy number-high resolution melting (LCN-HRM) enables the detection and identification by sequencing of low level mutations in cancer biopsies. Mol Cancer (2009) 1.17
Dopamine quinones activate microglia and induce a neurotoxic gene expression profile: relationship to methamphetamine-induced nerve ending damage. Ann N Y Acad Sci (2006) 1.15
Mephedrone, an abused psychoactive component of 'bath salts' and methamphetamine congener, does not cause neurotoxicity to dopamine nerve endings of the striatum. J Neurochem (2012) 1.13
A high-throughput protocol for mutation scanning of the BRCA1 and BRCA2 genes. BMC Cancer (2011) 1.12
BRAF inhibitor-driven tumor proliferation in a KRAS-mutated colon carcinoma is not overcome by MEK1/2 inhibition. J Clin Oncol (2013) 1.12
HES1 cooperates with pRb to activate RUNX2-dependent transcription. J Bone Miner Res (2006) 1.12
Assessing combined methylation-sensitive high resolution melting and pyrosequencing for the analysis of heterogeneous DNA methylation. Epigenetics (2011) 1.12
PPARgamma-independent induction of growth arrest and apoptosis in prostate and bladder carcinoma. BMC Cancer (2006) 1.11
Impact of young age on treatment efficacy and safety in advanced colorectal cancer: a pooled analysis of patients from nine first-line phase III chemotherapy trials. J Clin Oncol (2011) 1.07
Rapid detection of methylation change at H19 in human imprinting disorders using methylation-sensitive high-resolution melting. Hum Mutat (2008) 1.06
Loss of CDKN2A expression is a frequent event in primary invasive melanoma and correlates with sensitivity to the CDK4/6 inhibitor PD0332991 in melanoma cell lines. Pigment Cell Melanoma Res (2014) 1.05
Selective inhibition of proliferation in colorectal carcinoma cell lines expressing mutant APC or activated B-Raf. Int J Cancer (2009) 1.04
The relationship between unmet needs and distress amongst young people with cancer. Support Care Cancer (2011) 1.04
Analysing DNA methylation using bisulphite pyrosequencing. Methods Mol Biol (2011) 1.03
The prognostic significance of aldehyde dehydrogenase 1A1 (ALDH1A1) and CD133 expression in early stage non-small cell lung cancer. Thorax (2013) 1.03
An in vivo tumor model exploiting metabolic response as a biomarker for targeted drug development. Cancer Res (2005) 1.02
Direct genotyping of single nucleotide polymorphisms in methyl metabolism genes using probe-free high-resolution melting analysis. Cancer Epidemiol Biomarkers Prev (2008) 1.01
Genetic depletion of brain 5HT reveals a common molecular pathway mediating compulsivity and impulsivity. J Neurochem (2012) 1.01
A multisite blinded study for the detection of BRAF mutations in formalin-fixed, paraffin-embedded malignant melanoma. Sci Rep (2013) 1.01
Parathyroid hormone-related protein protects against mammary tumor emergence and is associated with monocyte infiltration in ductal carcinoma in situ. Cancer Res (2009) 0.99
Rapid analysis of heterogeneously methylated DNA using digital methylation-sensitive high resolution melting: application to the CDKN2B (p15) gene. Epigenetics Chromatin (2008) 0.99
DNA methylation profiling of phyllodes and fibroadenoma tumours of the breast. Breast Cancer Res Treat (2010) 0.99
Rarity of AKT1 and AKT3 E17K mutations in squamous cell carcinoma of lung. Cell Cycle (2010) 0.98
Mephedrone does not damage dopamine nerve endings of the striatum, but enhances the neurotoxicity of methamphetamine, amphetamine, and MDMA. J Neurochem (2013) 0.96
Detection of the transforming AKT1 mutation E17K in non-small cell lung cancer by high resolution melting. BMC Res Notes (2008) 0.95
Sensitive detection of KIT D816V in patients with mastocytosis. Clin Chem (2006) 0.95
Gender-specific activity of chemotherapy correlates with outcomes in chemosensitive cancers of young adulthood. Int J Cancer (2009) 0.94
Next-generation sequence analysis of cancer xenograft models. PLoS One (2013) 0.94
Molecular pathogenesis and targeted therapeutics in Ewing sarcoma/primitive neuroectodermal tumours. Clin Sarcoma Res (2012) 0.94
Identification of circulating tumour cells in early stage breast cancer patients using multi marker immunobead RT-PCR. J Hematol Oncol (2009) 0.93
Detection of BRAF mutations in patients with hairy cell leukemia and related lymphoproliferative disorders. Haematologica (2011) 0.93
Variable promoter region CpG island methylation of the putative tumor suppressor gene Connexin 26 in breast cancer. Carcinogenesis (2002) 0.92
Immune response to RB1-regulated senescence limits radiation-induced osteosarcoma formation. J Clin Invest (2013) 0.92
Intratumoral genetic heterogeneity in metastatic melanoma is accompanied by variation in malignant behaviors. BMC Med Genomics (2013) 0.91
The expression of the ubiquitin ligase SIAH2 (seven in absentia homolog 2) is mediated through gene copy number in breast cancer and is associated with a basal-like phenotype and p53 expression. Breast Cancer Res (2011) 0.91
DNA methylation of the ABO promoter underlies loss of ABO allelic expression in a significant proportion of leukemic patients. PLoS One (2009) 0.91
Cyclin E1 is amplified and overexpressed in osteosarcoma. J Mol Diagn (2011) 0.91
Methylation profiling of normal individuals reveals mosaic promoter methylation of cancer-associated genes. Oncotarget (2012) 0.91
Validation of a primer optimisation matrix to improve the performance of reverse transcription - quantitative real-time PCR assays. BMC Res Notes (2009) 0.90
Clinical and pathological associations of the activating RAC1 P29S mutation in primary cutaneous melanoma. Pigment Cell Melanoma Res (2014) 0.89
Differential mechanisms of CDKN2A (p16) alteration in oral tongue squamous cell carcinomas and correlation with patient outcome. Int J Cancer (2014) 0.89
Optimisation of the RT-PCR detection of immunomagnetically enriched carcinoma cells. BMC Cancer (2002) 0.89
Dopamine disposition in the presynaptic process regulates the severity of methamphetamine-induced neurotoxicity. Ann N Y Acad Sci (2008) 0.87
Investigating the potential role of genetic and epigenetic variation of DNA methyltransferase genes in hyperplastic polyposis syndrome. PLoS One (2011) 0.85
High frequency of germline TP53 mutations in a prospective adult-onset sarcoma cohort. PLoS One (2013) 0.85
Detection of NPM1 exon 12 mutations and FLT3 - internal tandem duplications by high resolution melting analysis in normal karyotype acute myeloid leukemia. J Hematol Oncol (2008) 0.85
Integrated mutation, copy number and expression profiling in resectable non-small cell lung cancer. BMC Cancer (2011) 0.85
Soman increases neuronal COX-2 levels: possible link between seizures and protracted neuronal damage. Neurotoxicology (2010) 0.84
DNA methylation analysis of the HIF-1α prolyl hydroxylase domain genes PHD1, PHD2, PHD3 and the factor inhibiting HIF gene FIH in invasive breast carcinomas. Histopathology (2010) 0.83
Cancer-associated neochromosomes: a novel mechanism of oncogenesis. Bioessays (2009) 0.83
Prevailing importance of the hedgehog signaling pathway and the potential for treatment advancement in sarcoma. Pharmacol Ther (2012) 0.83